{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:32:13Z","timestamp":1773286333442,"version":"3.50.1"},"reference-count":23,"publisher":"Japan Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1507\/endocrj.ej12-0293","type":"journal-article","created":{"date-parts":[[2013,2,2]],"date-time":"2013-02-02T00:33:35Z","timestamp":1359765215000},"page":"733-742","source":"Crossref","is-referenced-by-count":32,"title":["Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus"],"prefix":"10.1507","volume":"60","author":[{"given":"Tomoyuki","family":"Katsuno","sequence":"first","affiliation":[{"name":"Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Ikeda Hospital, Amagasaki 661-0002, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ida","sequence":"additional","affiliation":[{"name":"Ikeda Hospital, Amagasaki 661-0002, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichiro","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyoshi","family":"Namba","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, et al. (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. <i>Diabetes Care<\/i> 29: 1269-1274.","DOI":"10.2337\/dc05-1365"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, et al. (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. <i>N Engl J Med<\/i> 357: 1716-1730.","DOI":"10.1056\/NEJMoa075392"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, et al. (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. <i>Lancet<\/i> 371: 1073-1084.","DOI":"10.1016\/S0140-6736(08)60485-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Guler S, Vaz JA, Ligthelm R (2008) Intensification lessons with modern premixes: from clinical trial to clinical practice. <i>Diabetes Res Clin Pract<\/i> 81(Suppl.1): S23-30.","DOI":"10.1016\/j.diabres.2008.06.010"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Korytkowski M (2002) When oral agents fail: practical barriers to starting insulin. <i>Int J Obes Relat Metab Disord<\/i> 26(Suppl.3): S18-S24.","DOI":"10.1038\/sj.ijo.0802173"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. <i>Diabetes Obes Metab<\/i> 13: 7-18.","DOI":"10.1111\/j.1463-1326.2010.01306.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Drucker DJ, Nauck MA (2006) The incretin system: glucaon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. <i>Lancet<\/i> 368: 1696-1705.","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. <i>Diabetes Care<\/i> 30: 1979-1987.","DOI":"10.2337\/dc07-0627"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, et al. (2010) Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. <i>Endocr J<\/i> 57: 383-394.","DOI":"10.1507\/endocrj.K09E-272"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, et al. (2011) Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. <i>Diabetol Int<\/i> 2: 32-44.","DOI":"10.1007\/s13340-011-0022-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kashiwagi A, Kadowaki T, Tajima N, Nonaka K, Taniguchi T, et al. (2011) Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes. <i>J Diabetes Invest<\/i> 2: 381-390.","DOI":"10.1111\/j.2040-1124.2011.00120.x"},{"key":"12","unstructured":"12. Kadowaki T, Tajima N, Odawara M, Nishii M, Nonaka K, et al. (2008) Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes. ADA 68th Scientific Meeting Abstract No 2135-PO."},{"key":"13","unstructured":"13. Tajima N, Kadowaki T, Suzuki H, Sato A, Okuyama K, et al. (2010) Sitagliptin improved glycemic control and was well tolerated when added to voglibose monotherapy in patients with type 2 diabetes. ADA 70th Scientific Meeting Abstract No 575-P."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Vilsb&oslash;ll T, Rosenstock J, Yki-J&auml;rvinen H, Cefalu WT, Chen Y, et al. (2010) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 12: 167-177.","DOI":"10.1111\/j.1463-1326.2009.01173.x"},{"key":"15","unstructured":"15. Kadowaki T, Tajima N, Odawara M, Minamide T, Kawashima M, et al. (2011) Addition of sitagliptin, an oral, hightly-selective dipeptidyl peptidase-4 inhibitor, improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes on insulin monotherapy. ADA 71th Scientific Meeting Abstract No 1019-P."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. <i>Diabetol Int<\/i> 3: 8-10.","DOI":"10.1007\/s13340-012-0069-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, et al. (2008) Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. <i>Endocr J<\/i> 55: 503-507.","DOI":"10.1507\/endocrj.K07E-089"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, et al. (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. <i>J Clin Endocrinol Metab<\/i>. 91: 4612-4619.","DOI":"10.1210\/jc.2006-1009"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Goto A, Takaichi M, Kishimoto M, Takahashi Y, Kajio H, et al. (2010) Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. <i>Endocr J<\/i> 57: 237-244.","DOI":"10.1507\/endocrj.K09E-279"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hare KJ, Vilsb&oslash;ll T, Asmar M, Deacon CF, Knop FK, et al. (2010) The glucagonostatic and insulinotropic effects of glucagon-like peptide-1 contribute equally to its glucose-lowing action. <i>Diabetes<\/i> 59: 1765-1770.","DOI":"10.2337\/db09-1414"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, et al (2011) Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. <i>Endocr J<\/i> 58: 869-877.","DOI":"10.1507\/endocrj.K11E-129"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Aoki K, Kamiyama H, Yoshimura K, Shibuya M, Masuda K, et al. (2012) Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. <i>Acta Diabetol <\/i>49: 225-230.","DOI":"10.1007\/s00592-011-0322-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Yki-J&auml;rvinen H, Dressler A, Ziemen M, HOE 901\/300s study group. (2000) Less nocturnal hypoglycemia and better post-dinner glucose Control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. <i>Diabetes Care<\/i> 23: 1130-1136.","DOI":"10.2337\/diacare.23.8.1130"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/6\/60_EJ12-0293\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:34:15Z","timestamp":1618295655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/60\/6\/60_EJ12-0293\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej12-0293","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}